Aldeyra Therapeutics, Inc. (ALDX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 3.9100 |
| Open | 3.9400 |
| Bid | 3.9100 x 100 |
| Ask | 3.9800 x 100 |
| Day's Range | 3.8750 - 4.0000 |
| 52 Week Range | 1.4200 - 11.9700 |
| Volume | |
| Avg. Volume | 589,485 |
| Market Cap | 234.093M |
| Beta (5Y Monthly) | 1.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6400 |
| Earnings Date | May 02, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.25 |
ZacksIs Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
Here is how Aldeyra Therapeutics, Inc. (ALDX) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.
- Business Wire
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
LEXINGTON, Mass., April 18, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that the company will host a Research & Development Day from 9:00a.m. to 1:00p.m. ET on Thursday, April 25, 2024 in New York City.
ZacksAldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
Aldeyra (ALDX) rises 43% in one week, driven by plans to initiate a pivotal study to support the resubmission of reproxalap NDA for dry eye disease in the first half of 2024.
© 2024 Yahoo. All rights reserved.